Skip to main content
SpringerLink
Log in

Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases

  • Chapter
  • First Online:
Blistering Diseases

  • 1362 Accesses

Abstract

Mycophenolate mofetil is an immunosuppressive drug widely used in dermatology. It has been successfully applied for the treatment of various autoimmune bullous diseases, including pemphigus, bullous pemphigoid, and cicatricial pemphigoid, mostly as a steroid-sparing agent. Although a similar efficacy for MMF to other immunosuppressives has been reported in patients with pemphigus and bullous pemphigoid, its advantages over alternative immunosuppressive agents, such as azathioprine and cyclophosphamide, include its wide therapeutic index, mild side effects, and lack of major end-organ toxicity. This chapter reviews the drug properties of mycophenolate mofetil and assesses its role in the treatment of autoimmune bullous conditions, based on the current literature.

Disclosure

The authors have no financial interest in the manuscript.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CMV:

Cytomegalovirus

EC-MPS:

Enteric-coated mycophenolate sodium

GTP:

Guanosine triphosphate

IMPDH:

Inosine monophosphate dehydrogenase

iNOS:

Inducible nitric oxide synthase

MMF:

Mycophenolate mofetil

MPA:

Mycophenolic acid

MPAG:

Mycophenolic acid glucuronide

References

  1. Alsberg C, Black OF. Contribution to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Penicillium stoloniferum. Bull Burlingt Anim Indian US Dep Agric. 1913;270:1–47.

    Google Scholar 

  2. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14 Suppl 1:s2–8.

    Article  CAS  PubMed  Google Scholar 

  3. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993;136:5–28.

    Article  CAS  PubMed  Google Scholar 

  4. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268:27286–90.

    CAS  PubMed  Google Scholar 

  5. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.

    Article  CAS  PubMed  Google Scholar 

  6. Cohn RG, Mirkovich A, Dunlap B, Burton P, Chiu SH, Eugui E, Caulfield JP. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation. 1999;68:411–8.

    Article  CAS  PubMed  Google Scholar 

  7. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc. 1991;23:10–4.

    CAS  PubMed  Google Scholar 

  8. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc. 1993;25:67–70.

    CAS  PubMed  Google Scholar 

  9. Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S, Scholz M, Weber S, Encke A, Markus BH. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999;31:1250–2.

    Article  CAS  PubMed  Google Scholar 

  10. Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W. Antifibrotic actions of mycophenolic acid. Clin Transplant. 2006;20 Suppl 17:25–9.

    Article  PubMed  Google Scholar 

  11. Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol. 2003;134:63–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Lagaraine C, Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation. 2003;75:37S–42.

    Article  PubMed  Google Scholar 

  13. Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation. 1995;60:1143–8.

    Article  CAS  PubMed  Google Scholar 

  14. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315–24.

    Article  CAS  PubMed  Google Scholar 

  15. Sweeney MJ. Mycophenolic acid and its mechanism of action in cancer and psoriasis. Jpn J Antibiot. 1977;30(Suppl):85–92.

    CAS  PubMed  Google Scholar 

  16. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429–55.

    Article  CAS  PubMed  Google Scholar 

  17. Hoffman-La Roche Ltd. Cellcept (mycophenolate mofetil) [package insert], 1997.

    Google Scholar 

  18. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001;24:645–63.

    Article  CAS  PubMed  Google Scholar 

  19. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 1993;11 Suppl 8:S117–9.

    PubMed  Google Scholar 

  20. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139:739–42.

    Article  CAS  PubMed  Google Scholar 

  21. Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc. 2001;33:3238–40.

    Article  CAS  PubMed  Google Scholar 

  22. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–6.

    Article  CAS  PubMed  Google Scholar 

  23. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237–43.

    Article  CAS  PubMed  Google Scholar 

  24. Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant. 2006;25:935–41.

    Article  PubMed  Google Scholar 

  25. Chan L, Mulgaonkar S, Walker R, Arns W, Ambuhl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006;81:1290–7.

    Article  PubMed  Google Scholar 

  26. Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol. 2009;23:617–24.

    Article  CAS  PubMed  Google Scholar 

  27. Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007;20:229–38.

    Article  PubMed  Google Scholar 

  28. Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Broe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol. 2003;60:119–24.

    Article  CAS  PubMed  Google Scholar 

  29. Arbeiter K, Greenbaum L, Balzar E, Muller T, Hofmeister F, Bidmon B, Aufricht C. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol. 2000;14:195–7.

    Article  CAS  PubMed  Google Scholar 

  30. Mydlarski PR. Mycophenolate mofetil: a dermatologic perspective. Skin Therapy Lett. 2005;10:1–6.

    CAS  PubMed  Google Scholar 

  31. Orvis AK, Wesson SK, Breza Jr TS, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60:183–99; quiz 200–182.

    Article  PubMed  Google Scholar 

  32. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987;17:962–71.

    Article  CAS  PubMed  Google Scholar 

  33. Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17:75–92.

    Article  CAS  PubMed  Google Scholar 

  34. Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:903–6.

    Article  CAS  PubMed  Google Scholar 

  35. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant. 2000;14:136–8.

    Article  CAS  PubMed  Google Scholar 

  36. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant. 2000;15:711–4.

    Article  PubMed  Google Scholar 

  37. Weber SC, Uhlenberg B, Raile K, Querfeld U, Muller D. Polyoma virus-associated progressive multifocal leukoencephalopathy after renal transplantation: regression following withdrawal of mycophenolate mofetil. Pediatr Transplant. 2011;15:E19–24.

    Article  PubMed  Google Scholar 

  38. Manfro RC, Vedolin L, Cantarelli M, Oppitz P, Antunes AC, Rieder CR. Progressive multifocal leukoencephalopathy in a kidney transplant recipient after conversion to mycophenolic acid therapy. Transpl Infect Dis. 2009;11:189–90.

    Article  CAS  PubMed  Google Scholar 

  39. Lefevre G, Queyrel V, Maurage CA, Laurent C, Launay D, Lacour A, Charlanne H, Morell-Dubois S, Lambert M, Maillard H, et al. Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. J Neurol Sci. 2009;287:246–9.

    Article  PubMed  Google Scholar 

  40. US Food and Drug Administration. MedWatch the FDA safety information and adverse event reporting program. Cellcept (mycophenolate mofetil), April 2008. Available at: http://www.fda.gov/Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079813.htm. Accessed 15 Apr 2012.

  41. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997;37:445–9.

    Article  CAS  PubMed  Google Scholar 

  42. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis. 1999;34:296–303.

    Google Scholar 

  43. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1998;65:1450–4.

    Article  CAS  PubMed  Google Scholar 

  44. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation. 1999;68:391–96.

    Google Scholar 

  45. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5:2954–60.

    Article  CAS  PubMed  Google Scholar 

  46. O’Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:1186–91.

    Article  PubMed  Google Scholar 

  47. Lynch WS, Roenigk Jr HH. Mycophenolic acid for psoriasis. Arch Dermatol. 1977;113:1203–8.

    Article  CAS  PubMed  Google Scholar 

  48. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–702.

    Article  CAS  PubMed  Google Scholar 

  49. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol. 2004;103:1091–4.

    Article  PubMed  Google Scholar 

  50. Tjeertes IF, Bastiaans DE, van Ganzewinkel CJ, Zegers SH. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol. 2007;27:62–4.

    Article  CAS  PubMed  Google Scholar 

  51. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241–8.

    Article  PubMed  Google Scholar 

  52. US Food and Drug Administration. MedWatch the FDA safety information and adverse event reporting program. Cellcept (mycophenolate mofetil). October 2007. [updated11/27/2007] Available at: http://www.fda.gov/Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079813.htm. Accessed 15 Apr 2012.

  53. Perlis C, Pan T, McDonald C. Cytotoxic agents. In: Wolverton S, editor. Comprehensive dermatologic drug therapy. Philadelphia, Elsevier; 2007. p. 1099.

    Google Scholar 

  54. Gimenez F, Foeillet E, Bourdon O, Weller S, Garret C, Bidault R, Singlas E. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet. 2004;43:685–92.

    Article  CAS  PubMed  Google Scholar 

  55. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975;65:537–42.

    Article  CAS  PubMed  Google Scholar 

  56. Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol. 1979;1:531–7.

    Article  CAS  PubMed  Google Scholar 

  57. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135:54–6.

    Article  CAS  PubMed  Google Scholar 

  58. Chams-Davatchi C, Nonahal Azar R, Daneshpazooh M, Valikhani M, Hallaji Z, Barzegari M, Firouz AR, Zakeri M. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Ann Dermatol Venereol. 2002;129:23–5.

    CAS  PubMed  Google Scholar 

  59. Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, Black MM. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138–45.

    Article  CAS  PubMed  Google Scholar 

  60. Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol. 2011;64:490–4.

    Article  PubMed  Google Scholar 

  61. Esmaili N, Chams-Davatchi C, Valikhani M, Farshidfar F, Parvaneh N, Tamizifar B. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Eur J Dermatol. 2008;18:159–64.

    CAS  PubMed  Google Scholar 

  62. Bongiorno MR, Pistone G, Doukaki S, Arico M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J Dermatol. 2010;49:693–9.

    Article  CAS  PubMed  Google Scholar 

  63. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041–8.

    Article  CAS  PubMed  Google Scholar 

  64. Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krahn G, Kerscher M, Peter RU. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40:957–60.

    Article  CAS  PubMed  Google Scholar 

  65. Baskan EB, Yilmaz M, Tunali S, Saricaoglu H. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1432–4.

    Article  CAS  PubMed  Google Scholar 

  66. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447–54.

    Article  CAS  PubMed  Google Scholar 

  67. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi SZ, Seirafi H, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–8.

    Article  PubMed  Google Scholar 

  68. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–8.

    Article  PubMed  Google Scholar 

  69. Williams JV, Marks Jr JG, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol. 2000;142:506–8.

    Article  CAS  PubMed  Google Scholar 

  70. Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349:541.

    Article  CAS  PubMed  Google Scholar 

  71. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol. 1998;39:497–8.

    Article  CAS  PubMed  Google Scholar 

  72. Fox JC, Kenkare S, Petronic-Rosic V, Soltani K, Sethi A. Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy. Pediatr Dermatol. 2010;27:537–9.

    Article  PubMed  Google Scholar 

  73. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536–42.

    Article  CAS  PubMed  Google Scholar 

  74. Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2001;45:256–9.

    Article  CAS  PubMed  Google Scholar 

  75. Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat. 2006;17:370–6.

    Article  CAS  PubMed  Google Scholar 

  76. Ingen-Housz-Oro S, Prost-Squarcioni C, Pascal F, Doan S, Brette MD, Bachelez H, Dubertret L. Cicatricial pemphigoid: treatment with mycophenolate mofetil. Ann Dermatol Venereol. 2005;132:13–6.

    Article  CAS  PubMed  Google Scholar 

  77. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–32 e421–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Saw VP, Dart JK, Rauz S, Ramsay A, Bunce C, Xing W, Maddison PG, Phillips M. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115:253–61 e251.

    Article  PubMed  Google Scholar 

  79. Doycheva D, Deuter C, Blumenstock G, Stuebiger N, Zierhut M. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm. 2011;19:431–8.

    Article  CAS  PubMed  Google Scholar 

  80. Schattenkirchner S, Eming S, Hunzelmann N, Krieg T, Smola H. Treatment of epidermolysis bullosa acquisita with mycophenolate mofetil and autologous keratinocyte grafting. Br J Dermatol. 1999;141:932–3.

    Article  CAS  PubMed  Google Scholar 

  81. Kowalzick L, Suckow S, Ziegler H, Waldmann T, Ponnighaus JM, Glaser V. Mycophenolate mofetil in epidermolysis bullosa acquisita. Dermatology. 2003;207:332–4.

    Article  PubMed  Google Scholar 

  82. Tran MM, Anhalt GJ, Barrett T, Cohen BA. Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent. J Am Acad Dermatol. 2006;54:734–6.

    Article  PubMed  Google Scholar 

  83. Talhari C, Mahnke N, Ruzicka T, Megahed M. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. Clin Exp Dermatol. 2005;30:297–8.

    Article  CAS  PubMed  Google Scholar 

  84. Lewis MA, Yaqoob NA, Emanuel C, Potts AJ.Successful treatment of oral linear IgA disease using mycophenolate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:483–6.

    Article  CAS  PubMed  Google Scholar 

  85. Marzano AV, Ramoni S, Spinelli D, Alessi E, Berti E. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. J Dermatolog Treat. 2008;19:364–7.

    Article  CAS  PubMed  Google Scholar 

  86. Farley-Li J, Mancini AJ. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol. 2003;139:1121–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel

    Marina Eskin-Schwartz MD, PhD

  2. Skin Cancer Unit, Department of Dermatology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel

    Daniel Mimouni MD

Authors
  1. Marina Eskin-Schwartz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Mimouni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Mimouni MD .

Editor information

Editors and Affiliations

  1. Department of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia

    Dédée F. Murrell

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Eskin-Schwartz, M., Mimouni, D. (2015). Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases. In: Murrell, D. (eds) Blistering Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45698-9_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45698-9_48

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45697-2

  • Online ISBN: 978-3-662-45698-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation